22.40

2.99% 0.65

After Hours: 22.46 0.06 +0.27%

Definium Therapeutics Inc (DFTX)

Overview News Price History Discussions Forecast

Definium Therapeutics Inc stock is traded at $22.40, with a volume of 1.04M. It is up +2.99% in the last 24 hours and up +8.32% over the past month. Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Previous Close:

$21.75

Open:

$21.75

24h Volume:

1.04M

Relative Volume:

0.61

Market Cap:

$2.44B

Revenue:

Net Income/Loss:

$-183.79M

P/E Ratio:

-10.83

EPS:

-2.0691

Net Cash Flow:

$-131.84M

1W Performance:

+5.31%

1M Performance:

+8.32%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$21.70

$22.59

1-Week Range:

$20.27

$22.59

52-Week Range:

$14.62

$26.25

Definium Therapeutics Inc Stock (DFTX) Company Profile

Name

Definium Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

106

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

DFTX's Discussions on Twitter

Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DFTX Definium Therapeutics Inc	22.40	2.37B	0	-183.79M	-131.84M	-2.0691
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Stifel	Buy
Apr-10-26	Initiated	Piper Sandler	Overweight
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-30-26	Initiated	Jefferies	Buy
Oct-13-25	Initiated	Needham	Buy
Aug-04-25	Resumed	Oppenheimer	Outperform
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Definium Therapeutics Inc Stock (DFTX) Latest News

May 04, 2026

Definium Therapeutics (DFTX) Short Interest & Short Float | Updated May 2026 - MarketBeat

May 04, 2026

A Look At Definium Therapeutics (DFTX) Valuation As DT120 ODT Nears Key Phase 2 And Phase 3 Readouts - Yahoo Finance

May 04, 2026

May 03, 2026

Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 213% One Year Surge? - Sahm

May 03, 2026

Apr 30, 2026

Definium Therapeutics to hold live Q1 financial webcast on May 7 - Traders Union

Apr 30, 2026

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - The Joplin Globe

Apr 30, 2026

A Look At Definium Therapeutics (DFTX) Valuation After Recent Share Price Volatility - Sahm

Apr 30, 2026

Definium Therapeutics (DFTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Apr 30, 2026

Apr 29, 2026

Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN

Apr 29, 2026

Apr 28, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - MarketBeat

Apr 28, 2026

Can Definium Therapeutics' (DFTX) LSD Platform Strategy Reframe Its Risk Profile Across Brain Health Disorders? - simplywall.st

Apr 28, 2026

Apr 27, 2026

Definium Therapeutics (STU:MMQ0) Shiller PE Ratio : (As of May. 02, 2026) - GuruFocus

Apr 27, 2026

Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.7%Here's What Happened - MarketBeat

Apr 27, 2026

Definium Therapeutics (DFTX) details 2026 virtual meeting and equity plan vote - Stock Titan

Apr 27, 2026

These 3 Psychedelic Stocks Activated After Trump’s Executive Order - Investing.com

Apr 27, 2026

LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Apr 25, 2026

Apr 24, 2026